Abstract
Bisphosphonate osteonecrosis (BON) is a relatively recent adverse drug event that affects the oral cavity almost exclusively. It has been reported in individuals with metastatic breast, prostate, and lung cancer as well as in multiple myeloma. It has also been reported in a small subset of individuals who have been treated with bisphosphonate therapy for osteoporosis and Pagets disease of bone. Published studies to date have been characterized by relatively small sample sizes. Based on these studies, incidence appears to range between 0.1% and 11% depending on the population being studied and a number of other co-factors that have not been completely understood. The pathobiology of BON has not been fully elucidated and risk factors involved in the process need confirmation. Patients with this complication have altered quality of life and can suffer from discomfort and pain. Management is difficult and, while many treatment protocols have been proposed, at best they have only had partial success. This review of literature discusses a number of issues involving BON, with focus on the definition, possible association of BON and bisphosphonate therapy, pathobiology of BON and several additional research questions that need further investigation.
Keywords: Bisphosphonates, osteonecrosis, jaws, oral cavity, cancer, osteoporosis
Reviews on Recent Clinical Trials
Title: Bisphosphonate Osteonecrosis (BON): Unanswered Questions and Research Possibilities
Volume: 4 Issue: 2
Author(s): Cesar A. Migliorati, Mark M. Schubert and Douglas E. Peterson
Affiliation:
Keywords: Bisphosphonates, osteonecrosis, jaws, oral cavity, cancer, osteoporosis
Abstract: Bisphosphonate osteonecrosis (BON) is a relatively recent adverse drug event that affects the oral cavity almost exclusively. It has been reported in individuals with metastatic breast, prostate, and lung cancer as well as in multiple myeloma. It has also been reported in a small subset of individuals who have been treated with bisphosphonate therapy for osteoporosis and Pagets disease of bone. Published studies to date have been characterized by relatively small sample sizes. Based on these studies, incidence appears to range between 0.1% and 11% depending on the population being studied and a number of other co-factors that have not been completely understood. The pathobiology of BON has not been fully elucidated and risk factors involved in the process need confirmation. Patients with this complication have altered quality of life and can suffer from discomfort and pain. Management is difficult and, while many treatment protocols have been proposed, at best they have only had partial success. This review of literature discusses a number of issues involving BON, with focus on the definition, possible association of BON and bisphosphonate therapy, pathobiology of BON and several additional research questions that need further investigation.
Export Options
About this article
Cite this article as:
Migliorati A. Cesar, Schubert M. Mark and Peterson E. Douglas, Bisphosphonate Osteonecrosis (BON): Unanswered Questions and Research Possibilities, Reviews on Recent Clinical Trials 2009; 4 (2) . https://dx.doi.org/10.2174/157488709788185978
DOI https://dx.doi.org/10.2174/157488709788185978 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerium(III) and Neodymium(III) Complexes as Scavengers of X/XODerived Superoxide Radical
Medicinal Chemistry Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Subject Index To Volume-3
Letters in Drug Design & Discovery Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Muscle Metabolism and Exercise Capacity in Cachexia
Current Pharmaceutical Design A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets Feature Based Fusion of Multimodal Medical Image Slices with Combined Transforms
Current Medical Imaging Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design A Focus on Heme Oxygenase-1 (HO-1) Inhibitors
Current Medicinal Chemistry Design, Synthesis and In vitro Evaluation of Piperazine Incorporated Novel Anticancer Agents
Letters in Drug Design & Discovery Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets ABC Pumps and Their Role in Active Drug Transport
Current Topics in Medicinal Chemistry Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Effect of Particle Formulation on Dry Powder Inhalation Efficiency
Current Pharmaceutical Design Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
Clinical Cancer Drugs The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets